GE HealthCare Unveils Enhanced LesionID Pro at SNMMI Conference
Emphasizing a zero-click experience, the updated LesionID Pro software, to be introduced at the SNMMI conference, reportedly provides AI-powered automated insights into whole-body tumor burden with PET and SPECT imaging.
While manual segmentation of lesions and comparisons of PET and SPECT images would take hours to ascertain whole-body tumor burden, an emerging artificial intelligence (AI)-enabled software may provide significantly enhanced diagnostic efficiency.
The updated LesionID Pro software, which will be introduced by GE HealthCare at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference, features automated zero-click pre-processing of PET and SPECT images.
Powered by enhanced AI algorithms and designed with input from leading theranostics clinicians, the new LesionID Pro software, which reportedly offers automated analysis of whole-body tumor burden, is slated to be introduced at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference. (Image courtesy of GE HealthCare.)
“(Now) physicians can access critical, patient-specific insights — like tumor volume — without needing to spend hours manually segmenting lesions or aligning multiple scans. This not only helps speed up the diagnostic process but also helps clinicians make fast, informed decisions, which are crucial in cancer care,” noted Jean-Luc Procaccini, the president and CEO of molecular Imaging and computed tomography at GE HealthCare.
Powered by enhanced AI algorithms and designed with input from leading theranostics clinicians, the new LesionID Pro offers automated analysis of whole-body tumor burden, according to GE HealthCare and MIM Software, the developers of LesionID Pro.
Procaccini emphasized that the updated LesionID Pro can play a key role in monitoring the effectiveness of treatments.
“Monitoring treatment response is a critical part of theranostics, and LesionID Pro is designed to significantly streamline the process. By automating the pre-processing of imaging data and providing consistent, quantifiable tumor burden statistics, the software enables clinicians to track changes in tumor volume over time with greater accuracy and less effort,” maintained Procaccini. “This consistency is key for evaluating how well a therapy is working and making timely adjustments to treatment plans. Altogether, it supports precise, data-driven care decisions that can directly impact patient outcomes.”
GE HealthCare noted that LesionID Pro with automated pre-click processing is pending 510(k) clearance by the Food and Drug Administration (FDA).
ASCO: Study Reveals Significant Racial/Ethnic Disparities with PSMA PET Use for Patients with mPCa
May 30th 2025Latinx patients with metastatic prostate cancer were 63 percent less likely than non-Hispanic White patients to have PSMA PET scans, according to a study of 550 patients presented at the American Society of Clinical Oncology (ASCO) conference.
CT Perfusion Study Shows Enhanced Detection of Medium Vessel Occlusions with Emerging AI Software
May 21st 2025The Rapid CTP AI software offered 23 percent greater detection of medium vessel occlusions in comparison to the Viz CTP AI software, according to research presented at the European Stroke (Organization) Conference (ESOC).
Can AI Predict Future Lung Cancer Risk from a Single CT Scan?
May 19th 2025In never-smokers, deep learning assessment of single baseline low-dose computed tomography (CT) scans demonstrated a 79 percent AUC for predicting lung cancer up to six years later, according to new research presented today at the American Thoracic Society (ATS) 2025 International Conference.
